Despite our reports of safety and efficacy in a mouse OIR model [82], the therapeutic windows of anti-Scg3 still need to be precisely determined and compared with anti-VEGF in mice as well as non-murine preclinical models before we can advance the technology to our final goal of anti-Scg3 clinical trials for ROP. This evidence concerns the gene VEGFA and retinopathy of prematurity.